213 related articles for article (PubMed ID: 30583683)
1. Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer.
Ayadi EZ; Cherif B; Ben Hamed Y; Mokni M; Rebai A; Ayadi H; Jlidi R
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3557-3564. PubMed ID: 30583683
[TBL] [Abstract][Full Text] [Related]
2. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
3. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
5. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
[TBL] [Abstract][Full Text] [Related]
6. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
8. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
9. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
11. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
12. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
13. Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma.
Kim EJ; Kim SH; Park GE; Kang BJ; Song BJ; Kim YJ; Lee D; Ahn H; Kim I; Son YH; Grimm R
J Magn Reson Imaging; 2015 Dec; 42(6):1666-78. PubMed ID: 25919239
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 expression and triple negative profile in breast carcinoma.
Kallel-Bayoudh I; Hassen HB; Khabir A; Boujelbene N; Daoud J; Frikha M; Sallemi-Boudawara T; Aifa S; Rebaï A
Med Oncol; 2011 Dec; 28 Suppl 1():S55-61. PubMed ID: 20890735
[TBL] [Abstract][Full Text] [Related]
15. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up.
Veronese S; Mauri FA; Caffo O; Scaioli M; Aldovini D; Perrone G; Galligioni E; Doglioni C; Dalla Palma P; Barbareschi M
Int J Cancer; 1998 Feb; 79(1):13-8. PubMed ID: 9495351
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
17. Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset.
Lee WY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):310-5. PubMed ID: 12607598
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
19. [Expression of Ki67 and clinicopathological features in breast cancer].
Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
[TBL] [Abstract][Full Text] [Related]
20. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
